Eli Lilly announces new long-term Ebglyss data

More than 80% of adults and adolescents with moderate-to-severe atopic dermatitis who responded to Ebglyss treatment at Week 16 in the ADvocate 1 and 2 monotherapy trials and continued treatment for up to three years experienced sustained skin clearance with monthly maintenance dosing. Eli Lilly announced these new long-term results from the ADjoin long-term extension study, which will be presented at the European Academy of Dermatology and Venereology (EADV) Congress from Sept. 25-28 in Amsterdam, Netherlands. Ebglyss is an interleukin-13 inhibitor that selectively blocks IL-13 signaling with high binding affinity. The cytokine IL-13 is key in atopic dermatitis, driving the type-2 inflammatory cycle in the skin, leading to skin barrier dysfunction, itch, skin thickening and infection. Patients taking Ebglyss who completed 52 weeks in ADvocate 1 or 2 could enroll in ADjoin for an additional 100 weeks of continued treatment. Patients in this analysis of the long-term extension trial received treatment either 250 mg every two weeks or once monthly. The approved maintenance dose of Ebglyss is 250 mg Q4W. These data presented are part of ADjoin, the long-term extension study of the Ebglyss trials, and include participants who responded to Ebglyss treatment at Week 16 from ADvocate 1 and ADvocate 2. In total, 84% of these patients taking Ebglyss once monthly and 83% taking Ebglyss every two weeks maintained clear or almost-clear skin at three years. Overall, 87% of these patients taking Ebglyss once monthly and 79% taking Ebglyss every two weeks achieved or maintained at least 90% improvement in disease extent and severity at three years. In total, 83% of these patients taking Ebglyss once monthly and 91% taking Ebglyss every two weeks did not require either high-potency topical corticosteroids or systemic treatments. The safety profile of these patients taking Ebglyss in ADjoin was consistent with previous Ebglyss studies, and no new safety signals were observed up to three years of treatment. The majority of adverse events were mild or moderate. Less than three percent of patients experienced adverse events leading to treatment discontinuation. The most common side effects of Ebglyss were conjunctivitis, injection site reactions and shingles. Additional data from this clinical study is underway, with results to be presented at future congresses.